Asset Details
Do you wish to reserve the book?
Cancer risks in Jewish male BRCA1 and BRCA2 mutation carriers
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Cancer risks in Jewish male BRCA1 and BRCA2 mutation carriers
Do you wish to request the book?
Cancer risks in Jewish male BRCA1 and BRCA2 mutation carriers
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Cancer risks in Jewish male BRCA1 and BRCA2 mutation carriers
2015
Overview
Cancer risks and tumor types in male
BRCA1
and
BRCA2
mutation carriers are still unsettled. Cancer risks in men who were found to harbor a
BRCA1
(
n
= 150) or a
BRCA2
(
n
= 88) mutation or both (
n
= 2) were assessed by cross referencing with data on cancer occurrence in the Israeli National Cancer Registry. Incidence rates in mutation carriers were compared with men who were counseled, genotyped, and found not to harbor the familial mutation (true negative
n
= 122), and with standardized incidence rates (SIRs). Of 210 cancer-free individuals at initial counseling, 11 cancers were diagnosed after a mean follow-up of 5.06 ± 4.1 years (1064 person/years) compared with 1/122 in a BRCA true-negative man. The SIR for all
BRCA1/2
mutation carriers compared with the rates in the general population were elevated for pancreatic cancer [2.97 (95 % CI 1.83–4.29)] and breast cancer [16.44 (95 % CI 9.65–26.24)]. For prostate cancer these rates were 0.59 (95 % CI 0.4–0.84). Jewish
BRCA1/2
mutation carriers are at an increased risk for breast and pancreatic, but not prostate cancer. These cancer risks and the consequent recommendations, if validated, should be transmitted to carriers at test result disclosure.
Publisher
Springer US,Springer,Springer Nature B.V
